Identifying gene receptors for more effective drug treatment

Dr Nicholas Coupe is a clinical consultant at the Churchill hospital (NHS OUH Foundation Trust), specialising in treating patients with melanoma and lung cancer. After having trained as a medical oncologist  in Australia he carried out his D.Phil studies at Oxford as a CRUK Oxford Centre Clinical Research Training Fellow from 2015-2018.

Despite recent advances in the way melanoma is treated, many patients still succumb to the disease. An earlier clinical trial (AVAST-M) identified that patients with BRAF mutant melanoma (representing about half of all melanoma patients) are particularly sensitive to bevacizumab, a drug that inhibits VEGF, a growth factor that promotes new blood vessel growth. Nick’s work focused on identifying the mechanism through which the BRAF mutation in melanoma causes bevacizumab sensitivity, predominately by ascertaining links between the BRAF mutation and VEGF expression.The broader goals of his work were to identify additional therapeutic targets that could help treat patients with melanoma with a BRAF mutation.

Using bioinformatic approaches to analyse multiple data sets (including patient samples from the AVAST-M trial) he identified a number of genes that are overexpressed in BRAF mutant tumours and that one of theseplays a significant role in the secretion of VEGF. The gene Nick identified encodes a receptor which is of interest as it is a potential drug target. Blocking this receptor may potentially inhibit new blood vessel growth in BRAF mutant melanomas and could therefore one day evolve into a therapeutic strategy for patients with this disease.

 Some of Nick’s collaborators within Oxford are Prof Adrian Harris and Prof Francesca Buffa (Department of Oncology), Dr Ruud van Stiphout (Ludwig Institute for Cancer Research, Nuffield Department of Medicine), and Dr Naveed Akbar (Radcliffe Department of Medicine). Nick has been funded by CRUK.

Find out more about Nick’s work with patients on Imogen Cheese’s blog Melanoma Rollercoaster.

Nick’s CRUK #MyWisdom for Melanoma: “be sunsmart today, reduce your risk of melanoma tomorrow”.

Find out more about our research below

Study investigating targeted drug delivery by focused ultrasound for pancreatic cancer opens

University of Oxford researchers have begun recruitment to a study looking at whether chemotherapy medication can reach pancreatic tumours more effectively if encapsulated within a heat-sensitive shell and triggered with focused ultrasound.

Groundbreaking FOCUS4 clinical trials report their findings at ASCO

Principal Investigator Tim Maughan talks about the forward-thinking approach of the FOCUS4 cancer clinical trials and how they have helped shape the UK's fight against COVID-19
Doctor looking at skin

Higher testosterone levels in men linked to greater melanoma risk

New research from Dr Eleanor Watts at the Nuffield Department of Population Health has found this association for the first time

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.

Oxford spin out influencing patient care world wide

Oxford cancer research spin our Optellum has received FDA clearance for the world’s first AI-powered clinical decision support for early lung cancer diagnosis

Finding extracellular vesicle biomarkers for oesophageal cancer early detection

Prof Deborah Goberdhan’s lab is investigating extracellular vesicles and the proteins they express as potential biomarkers for the progression from Barrett’s Oesophagus to oesophageal cancer

Understanding how cancer arises from infected tissue

Dr Francesco Boccellato is investigating the mechanisms behind the pre-cancerous condition known as atrophic gastritis. This may help to identify those who may have cancer, as well as find new ways to prevent cancer from progressing
The NMR machine in the lab of James Larkins, with samples lined up to be analysed

Following the cancer metabolomic breadcrumb trail

By analysing the metabolic molecules that tumour cells leave behind, Dr James Larkin is investigating the applications of metabolomics in the early detection of many cancers.

Being a part of cancer drug discoveries

Susan Cakebread, gives her account of being on an experimental drug trial here in Oxford

SCALOP team discover new pancreatic cancer biomarker

The SCALOP clinical trial team have uncovered a new therapeutic target for locally advanced pancreatic cancer. Read more about it and the next steps for the SCALOP-2 trial.

New melanoma drug a step closer to the clinic

Clinical trials into the use of Tebentafusp for metastatic uveal melanoma have been conducted by the University of Oxford and Immunocore. The positive results of the most recent trial mean this drug could now be used in future treatment.

The search for pancreatic cancer biomarkers

Nuffield Department of Population Health researchers are using the China Kadoorie Biobank to identify potential protein biomarkers in the blood that could be used to predict the presence or development of pancreatic cancer

Detecting pancreatic cancer through blood tests

The Song Lab recently developed an effective and accurate way of detecting cancer biomarkers in the blood. Now, they are looking at the application of TAPS technology in pancreatic cancer

Innovative drug delivery techniques show promise in clinical trials

Dr Laura Spiers talks about the TarDox and PanDox trials, which are using novel drug delivery techniques to improve the uptake of chemotherapy drugs into pancreatic tumours and other cancers

Funding boost for OxPLoreD early detection study

UK Research and Innovation provides additional funds for whole genome sequencing as part of the OxPLoreD programme of research into high-risk conditions for blood cancer
Doctor looking at skin close up

Epigenetic markers for melanoma patient response to ICB therapy

Development fund winners Rosalin Cooper & Ben Fairfax are investigating the epigenetic landscape of melanoma patients and how it can impact patient sensitivity to ICB therapy

New melanoma cancer drug in development shows promise

University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma

QResearch researchers collaborate on two major cancer projects

Researchers in the Primary Care Epidemiology Group are joining two landmark projects to combine healthcare data and artificial intelligence to improve cancer diagnosis

Oxford to lead new programme of AI research to improve lung cancer screening

Science Minister Amanda Solloway today announced Oxford will lead a new national programme of AI research to improve lung cancer screening

What is a clinical trial? - new video series

What expect at every stage of an early phase clinical trial, so patients can make the most informed decision.

Patient reported outcomes in melanoma

,

The challenges of running platform trials

,

Oxford Expertise improving Cancer Care Worldwide

,

Predicting Bowel Cancer

,

Focussed ultrasound and nanomedicine offer new hope for improving effects of cancer drugs

Researchers have made a breakthrough in more precisely targeting…
,

Prognostic biomarkers discovered for patients with malignant pleural effusion

In a collaboration spanning multiple departments within Oxford…

Aspirin and acid reflux medication reduce the likelihood of patients with Barrett’s oesophagus developing oesophageal cancer.

Results of the AspECT clinical trial, coordinated by the CRUK…